🎉 M&A multiples are live!
Check it out!

Avidity Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Avidity Biosciences and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Avidity Biosciences Overview

About Avidity Biosciences

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.


Founded

2012

HQ

United States of America
Employees

391

Financials

LTM Revenue $10.0M

LTM EBITDA -$415M

EV

$1.7B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Avidity Biosciences Financials

Avidity Biosciences has a last 12-month revenue of $10.0M and a last 12-month EBITDA of -$415M.

In the most recent fiscal year, Avidity Biosciences achieved revenue of $10.9M and an EBITDA of -$376M.

Avidity Biosciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Avidity Biosciences valuation multiples based on analyst estimates

Avidity Biosciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $9.6M $10.9M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$233M -$376M XXX XXX XXX
EBITDA Margin -2442% -3452% XXX XXX XXX
Net Profit -$174M -$212M XXX XXX XXX
Net Margin -1820% -1948% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Avidity Biosciences Stock Performance

As of April 15, 2025, Avidity Biosciences's stock price is $27.

Avidity Biosciences has current market cap of $3.2B, and EV of $1.7B.

See Avidity Biosciences trading valuation data

Avidity Biosciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.7B $3.2B XXX XXX XXX XXX $-3.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Avidity Biosciences Valuation Multiples

As of April 15, 2025, Avidity Biosciences has market cap of $3.2B and EV of $1.7B.

Avidity Biosciences's trades at 174.7x LTM EV/Revenue multiple, and -4.2x LTM EBITDA.

Analysts estimate Avidity Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Avidity Biosciences and 10K+ public comps

Avidity Biosciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.7B XXX XXX XXX
EV/Revenue 159.7x XXX XXX XXX
EV/EBITDA -4.6x XXX XXX XXX
P/E -10.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -5.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Avidity Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Avidity Biosciences Valuation Multiples

Avidity Biosciences's NTM/LTM revenue growth is 4%

Avidity Biosciences's revenue per employee for the last fiscal year averaged $28K, while opex per employee averaged $1.0M for the same period.

Over next 12 months, Avidity Biosciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Avidity Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Avidity Biosciences and other 10K+ public comps

Avidity Biosciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 14% XXX XXX XXX XXX
EBITDA Margin -3452% XXX XXX XXX XXX
EBITDA Growth 61% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -3448% XXX XXX XXX XXX
Revenue per Employee $28K XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 791% XXX XXX XXX XXX
R&D Expenses to Revenue 2786% XXX XXX XXX XXX
Opex to Revenue 3577% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Avidity Biosciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Avidity Biosciences M&A and Investment Activity

Avidity Biosciences acquired  XXX companies to date.

Last acquisition by Avidity Biosciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Avidity Biosciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Avidity Biosciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Avidity Biosciences

When was Avidity Biosciences founded? Avidity Biosciences was founded in 2012.
Where is Avidity Biosciences headquartered? Avidity Biosciences is headquartered in United States of America.
How many employees does Avidity Biosciences have? As of today, Avidity Biosciences has 391 employees.
Who is the CEO of Avidity Biosciences? Avidity Biosciences's CEO is Ms. Sarah Boyce.
Is Avidity Biosciences publicy listed? Yes, Avidity Biosciences is a public company listed on NAS.
What is the stock symbol of Avidity Biosciences? Avidity Biosciences trades under RNA ticker.
When did Avidity Biosciences go public? Avidity Biosciences went public in 2020.
Who are competitors of Avidity Biosciences? Similar companies to Avidity Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Avidity Biosciences? Avidity Biosciences's current market cap is $3.2B
What is the current revenue of Avidity Biosciences? Avidity Biosciences's last 12-month revenue is $10.0M.
What is the current EBITDA of Avidity Biosciences? Avidity Biosciences's last 12-month EBITDA is -$415M.
What is the current EV/Revenue multiple of Avidity Biosciences? Current revenue multiple of Avidity Biosciences is 174.7x.
What is the current EV/EBITDA multiple of Avidity Biosciences? Current EBITDA multiple of Avidity Biosciences is -4.2x.
What is the current revenue growth of Avidity Biosciences? Avidity Biosciences revenue growth between 2023 and 2024 was 14%.
Is Avidity Biosciences profitable? Yes, Avidity Biosciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.